1 Consensus du groupe «RivaMos» et «hémostase» de la société suisse d’hématologie. Questions et réponses sur l’utilisation du rivaroxaban (Xarelto) dans la pratique. Rev Med Suisse. 2013;9:1375–85.
2 Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res. 2012;129(4):492–8.
3 Moner-Banet T, Alberio L, Bart PA. Does one dose really fit all? On the monitoring of direct oral anticoagulants: A review of the literature. Hämostaseologie. 2020 (doi: 10.1055/a-1113-0655).
4 Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118(3):437– 50.
5 Xarelto: summary of product characteristics [Internet]. European Medicines Agency; [cited 2019 Mar 5]. Available from:
https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
6 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16.
7 Eliquis: Summary of product characteristics [Internet]. European Medicines Agency; [cited 2019 Mar 4]. Available from:
https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf
8 Testa S, Dellanoce C, Paoletti O, Cancellieri E, Morandini R, Tala M, et al. Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function. Thromb Res. 2019;175:61–7.
9 Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallelgroup, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–41.
10 Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet Lond Engl. 2015;385(9984):2288–95.
11 Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MPA, Cohen AT, et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 27;116(4):747–53.
12 Tamingniau A, Douxfils J, Nicolas JB, Devalet B, Larock A S, Spinwine A et al. Pourquoi, quand et comment doser les nouveaux anticoagulants oraux. Rev Med Suisse. 2014;10:326–33.
13 Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Thromb Haemost. 2018;16(2):209–19.
14 Bertaggia-Calderara D, Kroll D, Gerschheimer C, Nicolas N, Nett P, Stirnimann G, et al. Effect of Rivaroxaban on thrombin generation in vivo. A study in obese patients. Int J Lab Hematol. 2018;40(1):e11–e4.